These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 35395742)
121. Time to major adverse drug reactions and its predictors among children on antiretroviral treatment at northwest Amhara selected public hospitals northwest; Ethiopia, 2023. Tsega BS; Habtamu A; Wubie M; Telayneh AT; Endalew B; Habtegiorgis SD; Birhanu MY; Kebede WM; Bishaw KA PLoS One; 2024; 19(10):e0309796. PubMed ID: 39361573 [TBL] [Abstract][Full Text] [Related]
122. Incidence and predictors of initial antiretroviral therapy regimen change among children in public health facilities of Bahir Dar City, Northwest Ethiopia, 2021: multicenter retrospective follow-up study. Azmeraw M; Workineh Y; Girma F; Kassaw A; Kerebeh G; Tsedalu A; Tigabu A; Mengesha T; Dagnaw E; Temesgen D; Beletew B; Dessie G; Dagne M BMC Pediatr; 2022 Apr; 22(1):186. PubMed ID: 35395742 [TBL] [Abstract][Full Text] [Related]
123. Incidence of anemia and predictors among Human Immunodeficiency Virus-infected children on antiretroviral therapy at public health facilities of Bahir Dar City, Northwest Ethiopia: multicenter retrospective follow up study. Kerebeh G; Ayalew Y; Kefale D; Chanie ES; Misganaw NM; Feleke DG; Kassaw A; Tigabu A; Bantie B; Tamirat M; Mengesha T; Azmeraw M; Endalamaw A BMC Pediatr; 2022 Mar; 22(1):115. PubMed ID: 35241033 [TBL] [Abstract][Full Text] [Related]
124. Incidence and predictors of treatment failure among children on first-line antiretroviral therapy in Amhara Region Referral Hospitals, northwest Ethiopia 2018: A retrospective study. Yihun BA; Kibret GD; Leshargie CT PLoS One; 2019; 14(5):e0215300. PubMed ID: 31042743 [TBL] [Abstract][Full Text] [Related]
125. Incidence and predictors of opportunistic infections among HIV-infected children on antiretroviral therapy at public health facilities of Southwest Ethiopia People Regional State, 2023: a multicenter retrospective follow-up study. Admasu N; Jihad M; Kebede A; Getnet M BMC Pediatr; 2024 Oct; 24(1):653. PubMed ID: 39394104 [TBL] [Abstract][Full Text] [Related]
126. Time to first optimal glycemic control and its predictors among type 1 diabetic children in Bahir Dar city public referral hospitals, North West Ethiopia: a retrospective follow up study. Meseret F; Belachew A; Tesfa G; Mengesha T; Embiale T; Alemu A; Dagne M BMC Pediatr; 2022 Sep; 22(1):563. PubMed ID: 36153485 [TBL] [Abstract][Full Text] [Related]
127. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors. Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE; PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999 [TBL] [Abstract][Full Text] [Related]
128. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676 [TBL] [Abstract][Full Text] [Related]
129. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008 [TBL] [Abstract][Full Text] [Related]
130. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449 [TBL] [Abstract][Full Text] [Related]
131. Incidence and risk factors of first-line antiretroviral treatment failure among human immunodeficiency virus-infected children in Amhara regional state, Ethiopia: a retrospective follow-up study. Sisay MM; Ayele TA; Gelaw YA; Tsegaye AT; Gelaye KA; Melak MF BMJ Open; 2018 Apr; 8(4):e019181. PubMed ID: 29626042 [TBL] [Abstract][Full Text] [Related]
132. Modification of Initial Highly Active Antiretroviral Therapy (HAART) Regimen in Paediatric HIV Patients. Low YS; Islahudin F; Razali KAM; Adnan S Open AIDS J; 2018; 12():11-19. PubMed ID: 29576815 [TBL] [Abstract][Full Text] [Related]
133. Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort. Wools-Kaloustian K; Marete I; Ayaya S; Sohn AH; Van Nguyen L; Li S; Leroy V; Musick BS; Newman JE; Edmonds A; Davies MA; Eboua FT; Obama MT; Yotebieng M; Sawry S; Mofenson LM; Yiannoutsos CT J Acquir Immune Defic Syndr; 2018 Jun; 78(2):221-230. PubMed ID: 29509590 [TBL] [Abstract][Full Text] [Related]
134. Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord Clin Infect Dis; 2018 Feb; 66(4):594-603. PubMed ID: 29029056 [TBL] [Abstract][Full Text] [Related]
135. First-line antiretroviral drug discontinuations in children. Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529 [TBL] [Abstract][Full Text] [Related]